GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIVUS Inc (STU:VIU1) » Definitions » Cyclically Adjusted PB Ratio

VIVUS (STU:VIU1) Cyclically Adjusted PB Ratio : (As of May. 15, 2024)


View and export this data going back to . Start your Free Trial

What is VIVUS Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


VIVUS Cyclically Adjusted PB Ratio Historical Data

The historical data trend for VIVUS's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIVUS Cyclically Adjusted PB Ratio Chart

VIVUS Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

VIVUS Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of VIVUS's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, VIVUS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VIVUS's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VIVUS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where VIVUS's Cyclically Adjusted PB Ratio falls into.



VIVUS Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

VIVUS's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2020 is calculated as:

For example, VIVUS's adjusted Book Value per Share data for the three months ended in Mar. 2020 was:

Adj_Book=Book Value per Share/CPI of Mar. 2020 (Change)*Current CPI (Mar. 2020)
=-6.285/108.9015*108.9015
=-6.285

Current CPI (Mar. 2020) = 108.9015.

VIVUS Quarterly Data

Book Value per Share CPI Adj_Book
201006 15.170 91.962 17.964
201009 12.703 92.162 15.010
201012 12.234 92.474 14.407
201103 10.956 94.283 12.655
201106 9.485 95.235 10.846
201109 12.308 95.727 14.002
201112 12.051 95.213 13.783
201203 24.727 96.783 27.823
201206 24.454 96.819 27.506
201209 21.138 97.633 23.578
201212 16.874 96.871 18.970
201303 13.464 98.209 14.930
201306 13.914 98.518 15.381
201309 11.385 98.790 12.550
201312 10.853 98.326 12.020
201403 9.900 99.695 10.814
201406 8.457 100.560 9.159
201409 7.930 100.428 8.599
201412 6.452 99.070 7.092
201503 6.112 99.621 6.681
201506 1.773 100.684 1.918
201509 0.418 100.392 0.453
201512 -0.625 99.792 -0.682
201603 -1.648 100.470 -1.786
201606 -2.515 101.688 -2.693
201609 -3.240 101.861 -3.464
201612 1.644 101.863 1.758
201703 1.592 102.862 1.685
201706 0.460 103.349 0.485
201709 0.028 104.136 0.029
201712 -0.745 104.011 -0.780
201803 -1.495 105.290 -1.546
201806 -2.248 106.317 -2.303
201809 -2.927 106.507 -2.993
201812 -3.308 105.998 -3.399
201903 -3.931 107.251 -3.992
201906 -4.363 108.070 -4.397
201909 -5.398 108.329 -5.427
201912 -5.851 108.420 -5.877
202003 -6.285 108.902 -6.285

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


VIVUS  (STU:VIU1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


VIVUS Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of VIVUS's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


VIVUS (STU:VIU1) Business Description

Industry
Traded in Other Exchanges
N/A
Address
900 East Hamilton Avenue, Suite 550, Campbell, CA, USA, 95008
VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

VIVUS (STU:VIU1) Headlines

No Headlines